drugset
Drugs / MK-0941
last change Jun 2010 re-read 2 minutes ago

MK-0941

Small molecule targets GCK via activation

Developed for
type 2 diabetes mellitus
Investigated by
Merck Sharp & Dohme LLC

Trials 11 · a red edge is where a trial was stopped

today NCT01106287 · Ph 1 NCT00830791 · Ph 1 NCT00792935 · Ph 2 NCT00824616 · Ph 2 NCT00873821 · Ph 1 NCT00767000 · Ph 2 NCT00912002 · Ph 1 NCT00754130 · Ph 1 NCT00567112 · Ph 1 NCT00511472 · Ph 1 NCT00511667 · Ph 1
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 18 trials
Phase 1 NCT01106287 Oct 2009 → Jan 2010 type 2 diabetes mellitus Merck Sharp & Dohme LLC Completed No outcome recorded
Phase 1 NCT00830791 Jan → Sep 2009 type 2 diabetes mellitus Merck Sharp & Dohme LLC Terminated No outcome recorded
Phase 1 NCT00873821 Dec 2008 → May 2009 type 2 diabetes mellitus Merck Sharp & Dohme LLC Completed No outcome recorded
Phase 1 NCT00912002 Oct → Nov 2008 type 2 diabetes mellitus Merck Sharp & Dohme LLC Completed No outcome recorded
Phase 1 NCT00754130 Sep → Oct 2008 type 2 diabetes mellitus Merck Sharp & Dohme LLC Completed No outcome recorded
Phase 1 NCT00567112 Nov 2007 → Feb 2008 type 2 diabetes mellitus Merck Sharp & Dohme LLC Completed No outcome recorded
Phase 1 NCT00511472 Jul 2007 → Apr 2008 type 2 diabetes mellitus Merck Sharp & Dohme LLC Completed No outcome recorded
Phase 1 NCT00511667 May 2007 → Apr 2008 type 2 diabetes mellitus Merck Sharp & Dohme LLC Completed No outcome recorded
Phase 23 trials
Phase 2 NCT00792935 Jan 2009 → Feb 2010 type 2 diabetes mellitus Merck Sharp & Dohme LLC Completed No outcome recorded
Phase 2 NCT00824616 Jan 2009 → May 2010 type 2 diabetes mellitus Merck Sharp & Dohme LLC Completed No outcome recorded
Phase 2 NCT00767000 Oct 2008 → Apr 2010 type 2 diabetes mellitus Merck Sharp & Dohme LLC Terminated No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 12 sources stand behind the page.

FieldValueCited text
Known as MK-0941 ClinicalTrials.gov intervention name — accepted as the source's own label NCT00792935 ↗
10

NCT00824616 ↗

NCT00567112 ↗

NCT00830791 ↗

NCT00767000 ↗

NCT00873821 ↗

NCT00754130 ↗

NCT01106287 ↗

NCT00912002 ↗

NCT00511667 ↗

NCT00511472 ↗
Action Activate “Hexokinase type IV activator” CHEMBL3580737 ↗
Modality Small molecule — CHEMBL3580737 ↗
Route Oral “oral compressed tablet (OCT) administered” NCT00567112 ↗
Target GCK “Hexokinase type IV activator” CHEMBL3580737 ↗